Opaganib is under clinical development by RedHill Biopharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Opaganib’s likelihood of approval (LoA) and phase transition for Bile Duct Cancer (Cholangiocarcinoma) took place on 12 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Opaganib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Opaganib overview

Opaganib (ABC-294640) is under development for the treatment of renal interstitial fibrosis, advanced, unresectable intra-hepatic, perihilar and extra-hepatic cholangiocarcinoma, non-small cell lung cancer, advanced solid tumors, pancreatic cancer, bile duct cancer (cholangiocarcinoma), colorectal cancer, metastatic castration resistant prostate cancer, influenza-virus infection and Pseudomonas aeruginosa-induced lung injury, pulmonary fibrosis, acute kidney injury, pneumonia, coronavirus disease (COVID-19) and ebola virus infection. It is administered orally as a capsule. It is an aryladamantane derivative. The drug candidate acts by targeting sphingosine kinase-2 (SK2). The drug candidate is a new chemical entity. It was also under development for multiple myeloma, hepatocellular carcinoma, diffuse large B-cell lymphoma, kaposi sarcoma and retinopathy, primary effusion lymphoma, liver transplantation, ulcerative colitis and rheumatoid arthritis. It was also under development as a radioprotectant for the prevention of mucositis and head and neck cancer.

RedHill Biopharma overview

RedHill Biopharma (RedHill) is a specialty biopharmaceutical company that develops and commercializes therapeutics for gastrointestinal (GI) diseases and cancer. The company’s commercial product portfolio consists of branded prescription drugs including a combination of omeprazole, amoxicillin and rifabutinomeprazole; naloxegol; and rifamycin. It is investigating its pipeline candidates for the treatment of Crohn’s disease, non-tuberculous mycobacterial infection (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleanser, cancer and novel coronavirus disease (COVID-19). The company has a subsidiary in the US. RedHill is headquartered in Tel Aviv, Israel.

Quick View Opaganib LOA Data

Report Segments
  • Innovator
Drug Name
  • Opaganib
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Infectious Disease
  • Oncology
  • Ophthalmology
  • Respiratory
  • Toxicology
Key Developers
Highest Development Stage
  • Phase III

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.